Paul F. Lizzul - Feb 10, 2022 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
Chief Medical Officer
Signature
/s/ Eric Loumeau, Attorney-in-Fact
Stock symbol
ANAB
Transactions as of
Feb 10, 2022
Transactions value $
$0
Form type
4
Date filed
2/14/2022, 03:55 PM
Previous filing
Nov 17, 2021
Next filing
Jun 27, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Stock Option (right to buy) Award $0 +70K $0.00 70K Feb 10, 2022 Common Stock 70K $30.44 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2023, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F2 In addition to the remaining options to purchase 70,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 135,000 shares of common stock, which options vest according to their terms, and (ii) 964 shares of common stock held directly.